Immune Checkpoint Inhibitor-Associated Hepatobiliary Toxicity: A Case of Concurrent Immune-Mediated Hepatitis and Acalculous Cholecystitis.
2/5 보강
OpenAlex 토픽 ·
Cancer Immunotherapy and Biomarkers
Cholangiocarcinoma and Gallbladder Cancer Studies
Liver Diseases and Immunity
Immune checkpoint inhibitors are associated with immune-related adverse events, including immune-mediated hepatitis, while acute acalculous cholecystitis remains exceedingly rare.
APA
Balakrishna Ravella, Eswar Gadde, Sravani Lokineni (2026). Immune Checkpoint Inhibitor-Associated Hepatobiliary Toxicity: A Case of Concurrent Immune-Mediated Hepatitis and Acalculous Cholecystitis.. ACG case reports journal, 13(4), e02097. https://doi.org/10.14309/crj.0000000000002097
MLA
Balakrishna Ravella, et al.. "Immune Checkpoint Inhibitor-Associated Hepatobiliary Toxicity: A Case of Concurrent Immune-Mediated Hepatitis and Acalculous Cholecystitis.." ACG case reports journal, vol. 13, no. 4, 2026, pp. e02097.
PMID
42005009 ↗
Abstract 한글 요약
Immune checkpoint inhibitors are associated with immune-related adverse events, including immune-mediated hepatitis, while acute acalculous cholecystitis remains exceedingly rare. We report a 52-year-old man with metastatic melanoma who developed concurrent grade 3 immune-mediated hepatitis and acute acalculous cholecystitis 2 weeks after combination ipilimumab-nivolumab therapy. He presented with right upper quadrant pain, jaundice, and marked transaminitis. Imaging showed gallbladder wall thickening with pericholecystic fluid without cholelithiasis, and alternative etiologies were excluded. The patient improved with conservative management without corticosteroids, with complete symptom resolution and biochemical normalization. This case highlights a rare dual hepatobiliary immune-related toxicity and the potential for conservative management in selected patients.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- SLC2A1 tumour-associated macrophages spatially control CD8 T cell function and drive resistance to immunotherapy in non-small-cell lung cancer.
- Distribution of Immune Cells in Tumor Microenvironment Correlates With Checkpoint Inhibitor Response in Nasopharyngeal Carcinoma: A Multiregional Study.
- Immune Checkpoint Inhibitors for Recurrent Hepatocellular Carcinoma After Liver Transplantation: Safety Under an Immunosuppression-Preserving Strategy.
- Enhanced efficacy and long-term survival with SBRT plus PD-1 inhibitors versus SBRT alone in unresectable HCC: a multicenter PSM study.
- TIM-3 inhibition enhances breast tumor progression and metastasis: A paradoxical immune checkpoint response.
- Association of immune-related adverse events with survival in patients receiving immune checkpoint inhibitor plus chemotherapy for lung cancer.